Video Experimental Relacionado
Updated: Sep 9, 2025
04:56
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
844
La importancia de las anomalías de la coagulación detectadas incidentalmente en niños
Gökçen Meral1, Ayça Koca Yozgat2, Vildan Çulha2
1Department of Pediatrics, Ankara City Hospital, Cankaya, Turkey.
Resumen
Las deficiencias leves del factor de coagulación son más frecuentes de lo previsto en niños con tiempo de protrombina (PT) prolongado incidentalmente o tiempo de tromboplastina parcial activado (aPTT). Estas deficiencias leves a menudo se presentan sin un historial de sangrado, y su importancia clínica sigue sin estar clara.
Área de la Ciencia:
- Hematología pediátrica
- Hemostasis y trombosis
- Coagulación clínica
Sus antecedentes:
- Un historial completo y un examen físico suelen identificar la mayoría de los trastornos hemorrágicos.
- Este estudio investigó trastornos hemostáticos en pacientes pediátricos con tiempo de protrombina (PT) prolongado incidentalmente o tiempo de tromboplastina parcial activado (aPTT).
Objetivo del estudio:
- Identificar la prevalencia y los tipos de trastornos hemostáticos en pacientes pediátricos con prolongación incidental de la TP/TPT.
- Evaluar la importancia clínica de las deficiencias leves de los factores en esta población.
Principales métodos:
- Se incluyeron pacientes pediátricos con PT prolongada y/ o aPTT incidental, sin enfermedad hematológica previa.
- Se analizaron las actividades de los factores de coagulación. Se realizaron pruebas de anticuerpos antifosfolípidos y anticoagulantes para lupus en pacientes con estudios de mezcla anormales.
Principales resultados:
- De los 103 pacientes, 50 tenían anormalidades persistentes de PT/ aPTT tras la reevaluación.
- La coagulopatía se identificó en el 30% de la cohorte total (60% de las personas con anormalidades persistentes).
- Las deficiencias más frecuentes incluyen el Factor XII (5,8%), el Factor XI (4,8%) y el Factor VII (2,9%).
Conclusiones:
- Las deficiencias leves del factor de coagulación son más frecuentes de lo esperado en los niños con prolongación incidental de la PT/aPTT.
- Estas deficiencias leves pueden ocurrir en pacientes sin antecedentes hemorrágicos.
- La importancia clínica y las implicaciones de estas deficiencias leves del factor son a menudo desconocidas.
Videos de Conceptos Relacionados
01:24Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
01:09Coagulation
7.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.4K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
01:20Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K
01:05Introduction to Hemostasis
8.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.9K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K